Sanofi Q3 Net Sales Up 16%; Dupixent Posts Second-Highest Quarter Ever as Patent Cliff Pressure Looms
nashnova research
Sanofi's third-quarter net sales hit €14.44 billion, up 16.2% year-on-year, driven by a €5.7 billion Dupixent quarter — its second-highest ever — but the blockbuster drug begins losing patent protection in the early 2030s, and a credible replacement revenue source is still missing.
What made this quarter so strong?
Q3 net sales reached €14.44 billion, up 16.2% reported and 14.3% at constant exchange rates.
Adjusted earnings per share came in at €3.55, far above the analyst consensus of €2.80. This means → it was not just a volume beat; profit conversion also outpaced expectations.
Sanofi raised full-year guidance for the second consecutive quarter: sales growth now expected at "low double digits" (up from 10%), adjusted EPS at "mid-teens" growth.
Why is Dupixent the only star of the show?
Dupixent — a biologic that treats atopic dermatitis, asthma, and other inflammatory conditions — posted €5.7 billion in quarterly sales, up 34.8%, topping the €5.0 billion mark for only the second time. Analysts had expected €5.2 billion.
In plain terms = nearly 40% of Sanofi's revenue this quarter came from a single drug.
This reflects a deepening dependency risk: the higher Dupixent's contribution, the steeper the revenue cliff when its patents expire in the early 2030s.
What happened on the vaccine and cost side?
The vaccine business was a drag. Flu vaccines and Beyfortus — a drug that prevents respiratory syncytial virus in infants — came under pressure in the U.S., pulling overall vaccine sales lower.
Separately, selling and promotional expenses came in below expectations. This means → part of the profit beat came from spending less, not just selling more.
How is Sanofi preparing for the "post-Dupixent era"?
New CEO Bénédicte de La Roncière stated the top priority clearly: "protecting earnings through Dupixent's patent expiry." The entire organization is being realigned around that goal.
She has halted several pipeline programs she views as unpromising and replaced R&D head Houman Ashrafian with Paulo Fontoura, a former Roche executive.
In plain terms = the new management playbook is "cut, reshuffle, focus" — the standard move when a big pharma company faces a patent cliff, the industry term for the sharp revenue drop once generics flood in after a key drug's patent expires.
Can new products and M&A fill the gap?
Recently launched drugs are starting to contribute: Altuviiio (for hemophilia A) and Rezurock (for chronic graft-versus-host disease) both beat sales expectations last quarter. The CFO said new-launch revenue share is "higher than in prior periods."
On M&A, CFO François-Xavier Roger said Sanofi is looking for "larger deals than in the past," most likely late-stage assets. This means → management wants to buy drugs close to market launch, not gamble on early-stage R&D.
Earlier this year, Sanofi and Dupixent co-developer Regeneron agreed to expand their partnership in a deal that could pay Regeneron up to $8 billion.
Why isn't the market convinced yet?
Sanofi shares are down roughly 8% year-to-date, weighed down by disappointing clinical-trial results — including amlitelimab, an experimental drug for atopic dermatitis.
The company expects to update its strategic priorities before year-end. This reflects what the market is really waiting for: not another strong quarter, but a credible roadmap for the post-Dupixent era.
In plain terms = no matter how good the current numbers look, investors keep asking the same question — after 2030, what fills the hole?
市场有风险，内容仅供研究参考，不构成投资建议。